Smart Allostery Platform is HotSpot Therapeutics' allosteric drug discovery platform for targeting disease-driving proteins.
The Smart Allostery Platform is built on three integrated modules: SpotFinder identifies natural allosteric hotspots across the proteome, SpotCapture characterizes these regulatory sites, and SpotBinder designs small molecules that bind them. The platform draws on a library of approximately 800 million compounds and a catalog of roughly 1,500 proteins with natural regulatory hotspots.
HotSpot Therapeutics applies the platform to target disease-driving proteins that conventional approaches struggle to drug. The company states that approximately 85% of proteins considered undruggable are addressable through their natural hotspots, expanding the range of targets its discovery programs can pursue.
| Attribute | Smart Allostery Platform | Induced Allosteric Drug Discovery Platform | |
|---|---|---|---|
| Provider |  |  | |
| Founded | 2017 | 2015 | |
| Sells To | Enterprise | Enterprise, Government | |
| Pricing Model | Recurring, Software | Recurring | |
| Ownership | Private equity-backed, Venture-backed | Public |
Provider
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private equity-backed, Venture-backed
Provider
Founded 2015
Sells To Enterprise, Government
Pricing Model Recurring
Ownership Public
Allosteric screening and synthetic lethality platforms with 200k library.
Dynamo Platform is Relay Therapeutics' Motion-Based Drug Design platform for finding novel allosteric binding sites on validated targets.
Gain Therapeutics platform using artificial intelligence and virtual screening for allosteric drug discovery.
Allosteric screening and synthetic lethality platforms with 200k library.
Dynamo Platform is Relay Therapeutics' Motion-Based Drug Design platform for finding novel allosteric binding sites on validated targets.
Gain Therapeutics platform using artificial intelligence and virtual screening for allosteric drug discovery.